End Points and Clinical Trial Design in Pulmonary Arterial Hypertension

Journal of the American College of Cardiology

Volumn 54, Issue 1 SUPPL. 1, 2009, Pages

  McLaughlin, Vallerie V ^a   Badesch, David B ^b   Delcroix, Marion ^c   Fleming, Thomas R ^d   Gaine, Sean P ^e   Galiè, Nazzareno ^f   Gibbs, J Simon R ^g   Kim, Nick H ^h   Oudiz, Ronald J ⁱ   Peacock, Andrew ^j   Provencher, Steeve ^k   Sitbon, Olivier ^l   Tapson, Victor F ^m   Seeger, Werner ⁿ  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITY OF WASHINGTON   (United States)

^e MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ HARBOR UCLA MEDICAL CENTER   (United States)

^j UNIVERSITY OF GLASGOW   (United Kingdom)

^k UNIVERSITÉ LAVAL   (Canada)

^l HÔPITAL ANTOINE BÉCLÈRE   (France)

^m DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁿ JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

more..

Author keywords

clinical trial design; end points; PAH

Indexed keywords

BERAPROST; BIOLOGICAL MARKER; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTANOID; SILDENAFIL; SITAXSENTAN;

CLINICAL RESEARCH; DIAGNOSTIC IMAGING; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; EXERCISE TEST; HEMODYNAMIC PARAMETERS; HUMAN; LIVER TOXICITY; METHODOLOGY; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; EXERCISE TEST; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME;

EID: 67649574735     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.04.007     Document Type: Review

References (100)

1. Wigley F.M., Lima J.A.C., Mayes M., McLain D., Chapin J.L., and Ward-Able C. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER Study). Arthritis Rheum 52 (2005) 2125-2132
2. Humbert M., Sitbon O., Chaouat A., et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 173 (2006) 1023-1030
3. Peacock A.J., Murphy N.F., McMurray J.J.V., Caballero L., and Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 30 (2007) 104-109
4. Thenappan T., Shah S.J., Rich S., and Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J 30 (2007) 1103-1110
5. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 (2002) 896-903
6. Olschewski H., Simonneau G., Galiè N., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347 (2002) 322-329
7. Oudiz R.J., Schilz R.J., Barst R.J., et al., Treprostinil Study Group. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 126 (2004) 420-427
8. Williams M.H., Das C., Handler C.E., et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 92 (2006) 926-932
9. McLaughlin V.V., Presberg K.W., Doyle R.L., et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126 (2004) 78S-92S
10. Badesch D.B., Tapson V.F., McGoon M.D., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 132 (2000) 425-434
11. Galiè N., Beghetti M., Gatzoulis M.A., et al., Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 114 (2006) 48-54
12. Yi E.S., Kim H., Ahn H., et al. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension: a morphometric and immunohistochemical study. Am J Respir Crit Care Med 162 (2000) 1577-1586
13. Galiè N., Torbicki A., Barst R., et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 25 (2004) 2243-2278
14. Anthi A., Machado R.F., Jison M.L., et al. Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med 175 (2007) 1272-1279
15. Krowka M.J., Swanson K.L., Frantz R.P., McGoon M.D., and Wiesner R.H. Portopulmonary hypertension: results from a 10-year screening algorithm. Hepatology 44 (2006) 1502-1510
16. Galiè N., Humbert M., Vachiéry J.L., et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. The Arterial Pulmonary Hypertension and Beraprost European Trial (ALPHABET) Study Group. J Am Coll Cardiol 39 (2002) 1496-1502
17. Jaïs X., D'Armini A.M., Jansa P., et al., BENEFiT Study Group. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension, a randomized, placebo-controlled trial. J Am Coll Cardiol 52 (2008) 2127-2134
18. Simonneau G., Barst R.J., Galiè N., et al., Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165 (2002) 800-804
19. Langleben D., Christman B.W., Barst R.J., et al. Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. Am Heart J 143 (2002) e4
20. Barst R.J., McGoon M., McLaughlin V., et al., Beroprost Study Group. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41 (2003) 2119-2125
21. Galiè N., Ghofrani H.A., Torbicki A., et al., Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 (2005) 2148-2157
22. Barst R.J., Langleben D., Badesch D., et al., STRIDE-2 Study Group. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 47 (2006) 2049-2056
23. McLaughlin V.V., Oudiz R.J., Frost A., et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 174 (2006) 1257-1263
24. Galiè N., Badesch D., Oudiz R., et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 46 (2005) 529-535
25. Guyatt G.H., Sullivan M.J., Thompson P.J., et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 132 (1985) 919-923
26. Miyamoto S., Nagaya N., Satoh T., et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161 (2000) 487-492
27. Sciurba F., Criner G.J., Lee S.M., et al., National Emphysema Treatment Trial Research Group. Six-minute walk distance in chronic obstructive pulmonary disease: reproducibility and effect of walking course layout and length. Am J Respir Crit Care Med 167 (2003) 1522-1527
28. Nogueira P.A., Leal A.C., Pulz C., Nogueira I.D., and Filho J.A. Clinical reliability of the 6 minute corridor walk test performed within a week of a myocardial infarction. Int Heart J 47 (2006) 533-540
29. Eaton T., Young P., Milne D., and Wells A.U. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 171 (2005) 1150-1157
30. Macchia A., Marchioli R., Marfisi R., et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 153 (2007) 1037-1047
31. Frost A.E., Langleben D., Oudiz R., et al., STRIDE-1 Study Group. The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. Vascul Pharmacol 43 (2005) 36-39
32. Sun X.-G., Hansen J.E., Oudiz R.J., and Wasserman K. Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation 104 (2001) 429-435
33. Raeside D.A., Smith A., Brow A., et al. Pulmonary artery pressure measurement during exercise testing in patients with suspected pulmonary hypertension. Eur Respir J 16 (2000) 282-287
34. Wensel R., Opitz C.F., Anker S.D., et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 106 (2002) 319-324
35. Barst R.J., Langleben D., Frost A., et al. Sitaxsentan therapy for pulmonary arterial hypertension. The STRIDE-1 Study Group. Am J Respir Crit Care Med 169 (2004) 441-447
36. Oudiz R.J., Barst R.J., Hansen J.E., et al. Cardiopulmonary exercise testing and six-minute walk correlations in pulmonary arterial hypertension. Am J Cardiol 997 (2006) 123-126
37. Oga T., Nishimura K., Tsukino M., Hajiro T., Ikeda A., and Izumi T. The effects of oxitropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease: a comparison of three different exercise tests. Am J Respir Crit Care Med 161 (2000) 1897-1901
38. Sastry B.K., Narasimhan C., Reddy N.K., and Raju B.S. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 43 (2004) 1149-1153
39. Gomberg-Maitland M., Tapson V.F., Benza R.L., et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 172 (2005) 1586-1589
40. Tapson V.F., Gomberg-Maitland M., McLaughlin V.V., et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 129 (2006) 683-688
41. Channick R.N., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 358 (2001) 1119-1123
42. Galiè N., Rubin L.J., Hoeper M.M., et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371 (2008) 2093-2100
43. Galiè N., Olschewski H., Oudiz R.J., et al., ARIES Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117 (2008) 3010-3019
44. Simmoneau G., Rubin L.J., Galiè N., et al., PACES Study Group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 149 (2008) 521-530
45. Barst R., Badesch B.D., Fleming T., et al. Risk of mortality after hospitalization for pulmonary arterial hypertension. Am J Respir Crit Care Med 171 (2007) A1003 (Abstract)
46. Mahler D.A., Weinberg D.H., Wells C.K., and Feinstein A.R. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 85 (1984) 751-758
47. Feinstein A.R., Fisher M.B., and Pigeon J.G. Changes in dyspnea-fatigue ratings as indicators of quality of life in the treatment of congestive heart failure. Am J Cardiol 64 (1989) 50-55
48. Mahler D.A., and Horowitz M.B. Perception of breathlessness during exercise in patients with respiratory disease. Med Sci Sports Exerc 26 (1994) 1078-1081
49. Wilson R.C., and Jones P.W. A comparison of the visual analogue scale and modified Borg scale for the measurement of dyspnoea during exercise. Clin Sci (Lond) 76 (1989) 277-282
50. Mador M.J., Rodis A., and Magalang U.J. Reproducibility of Borg scale measurements of dyspnea during exercise in patients with COPD. Chest 107 (1995) 1590-1597
51. Killian K.J., Leblanc P., Martin D.H., Summers E., Jones N.L., and Campbell E.J.M. Exercise capacity and ventilatory, circulatory, and symptom limitation in patients with chronic airflow limitation. Am Rev Respir Dis 146 (1992) 935-940
52. Guyatt G.H., Nogradi S., Halcrow S., Singer J., Sullivan M.J., and Fallen E.L. Development and testing of a new measure of health status for clinical trials in heart failure. J Gen Intern Med 4 (1989) 101-107
53. Borg G.A. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 14 (1982) 377-381
54. Jones P.W., Quirk F.H., Baveystock C.M., and Littlejohns P. A self-complete measure of health status for chronic airflow limitation: the St. George's Respiratory Questionnaire. Am Rev Respir Dis 145 (1992) 1321-1327
55. Rector T.S., Kubo S.H., and Cohn J.N. Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo. Am J Cardiol 71 (1993) 1106-1107
56. Ware Jr. J.E., and Sherbourne C.D. The MOS 36-item short-form health survey (SF-36): I. conceptual framework and item selection. Med Care 30 (1992) 473-483
57. Taichman D.B., Shin J., Hud L., et al. Health-related quality of life in patients with pulmonary arterial hypertension. Respir Res 6 (2005) 92
58. McKenna S.P., Doughty N., Meads D.M., Doward L.C., and Pepke-Zaba J. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res 15 (2006) 103-115
59. D'Alonzo G.E., Barst R.J., Ayres S.M., et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 115 (1991) 343-349
60. Eysmann S.B., Palevsky H.I., Reichek N., Hackney K., and Douglas P.S. Two-dimensional and Doppler-echocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension. Circulation 80 (1989) 353-360
61. Fuster V., Steele P.M., Edwards W.D., Gersh B.J., McGoon M.D., and Frye R.L. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70 (1984) 580-587
62. Kanemoto N. Natural history of pulmonary hemodynamics in primary pulmonary hypertension. Am Heart J 114 (1987) 407-413
63. Galiè N., Hinderliter A.L., Torbicki A., et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 41 (2003) 1380-1386
64. Tei C., Ling L.H., Hodge D.O., et al. New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function-a study in normals and dilated cardiomyopathy. J Cardiol 26 (1995) 357-366
65. Forfia PR, Fisher MR Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 1006;174:1034-41.
66. Lorenz C.H., Walker E.S., Morgan V.L., Klein S.S., and Graham Jr. T.P. Normal human right and left ventricular mass, systolic function, and gender differences by cine magnetic resonance imaging. J Cardiovasc Magn Reson 1 (1999) 7-21
67. Marcus J.T., Vonk Noordegraaf A., Roeleveld R.J., et al. Impaired left ventricular filling due to right ventricular pressure overload in primary pulmonary hypertension: noninvasive monitoring using MRI. Chest 119 (2001) 1761-1765
68. Paz R., Mohiaddin R.H., and Longmore D.B. Magnetic resonance assessment of the pulmonary arterial trunk anatomy, flow, pulsatility and distensibility. Eur Heart J 14 (1993) 1524-1530
69. Tardivon A.A., Mousseaux E., Brenot F., et al. Quantification of hemodynamics in primary pulmonary hypertension with magnetic resonance imaging. Am J Respir Crit Care Med 150 (1994) 1075-1080
70. van Wolferen S.A., Marcus J.T., Boonstra A., et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J 28 (2007) 1250-1257
71. Wilkins M.R., Paul G.A., Strange J.W., et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med 171 (2005) 1292-1297
72. Benza R., Biederman R., Murali S., and Gupta H. Role of cardiac magnetic resonance imaging in the management of patients with pulmonary arterial hypertension. J Am Coll Cardiol 52 (2008) 1683-1692
73. Tulevski I.I., Groenink M., van der Wall E.E., et al. Increased brain and atrial natriuretic peptides in patients with chronic right ventricular pressure overload: correlation between plasma neurohormones and right ventricular dysfunction. Heart 86 (2001) 27-30
74. Blyth K.G., Groenning B.A., Mark P.B., et al. NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension. Eur Respir J 29 (2007) 737-744
75. Gan C.T., McCann G.P., Marcus J.T., et al. NT-proBNP reflects right ventricular structure and function in pulmonary hypertension. Eur Respir J 28 (2006) 1190-1194
76. Downie P.F., Talwar S., Squire I.B., Davies J.E., Barnett D.B., and Ng L.L. Assessment of the stability of N-terminal pro-brain natriuretic peptide in vitro: implications for assessment of left ventricular dysfunction. Clin Sci (Lond) 97 (1999) 255-258
77. Fijalkowska A., Kurzyna M., Torbicki A., et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 129 (2006) 1313-1321
78. Mukerjee D., Yap L.B., Holmes A.M., et al. Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Respir Med 97 (2003) 1230-1236
79. Nagaya N., Nishikimi T., Uematsu M., et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102 (2000) 865-870
80. Torbicki A., Kurzyna M., Kuca P., et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 108 (2003) 844-848
81. Braghiroli A., Sacco C., Erbetta M., Ruga V., and Donner C.F. Overnight urinary uric acid: creatinine ratio for detection of sleep hypoxia: validation study in chronic obstructive pulmonary disease and obstructive sleep apnea before and after treatment with nasal continuous positive airway pressure. Am Rev Respir Dis 148 (1993) 173-178
82. Oya H., Nagaya N., Satoh T., et al. Haemodynamic correlates and prognostic significance of serum uric acid in adult patients with Eisenmenger syndrome. Heart 84 (2000) 53-58
83. Saito H., Nishimura M., Shibuya E., et al. Tissue hypoxia in sleep apnea syndrome assessed by uric acid and adenosine. Chest 122 (2002) 1686-1694
84. Nagaya N., Uematsu M., Satoh T., et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med 160 (1999) 487-492
85. Shitrit D., Bendayan D., Bar-Gil-Shitrit A., et al. Significance of a plasma D-dimer test in patients with primary pulmonary hypertension. Chest 122 (2002) 1674-1678
86. Rubens C., Ewert R., Halank M., et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 120 (2001) 1562-1569
87. Ghofrani H.A., Wiedemann R., Rose F., et al. Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: responders versus nonresponders. Eur Respir J 19 (2002) 664-671
88. Friedman R., Mears J.G., and Barst R.J. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 96 (1997) 2782-2784
89. Bogdan M., Humbert M., Francoual J., et al. Urinary cGMP concentrations in severe primary pulmonary hypertension. Thorax 53 (1998) 1059-1062
90. Taubes G. Use of placebo controls in clinical trials disputed. Science 267 (1995) 25-26
91. Galiè N., Manes A., Negro L., Palazzini M., Bacchi-Reggiani M.L., and Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 30 (2009) 394-403
92. Ghofrani H.A., Rose F., Schermuly R.T., et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 42 (2003) 158-164
93. Hoeper M.M., Oudiz R.J., Peacock A., et al. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol 43 (2004) 48S-55S
94. Gomberg-Maitland M., McLaughlin V., Gulati M., and Rich S. Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. Am J Cardiol 96 (2005) 1334-1336
95. Oudiz R.J., Roveran G., Hansen J.E., Sun X.G., and Wasserman K. Effect of sildenafil on ventilatory efficiency and exercise tolerance in pulmonary hypertension. Eur J Heart Fail 9 (2007) 917-921
96. Hoeper M.M., Leuchte H., Halank M., et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 28 (2006) 691-694
97. McLaughlin V. Long-term ambrisentan therapy for pulmonary arterial hypertension in patients who previously received placebo in ARIES-1 or ARIES-2. Paper presented at: Annual Meeting of the American Thoracic Society; May 16-21 (2008) Toronto, Canada
98. Frost A.E., McLaughlin V.V., Oudiz R.J., et al. STEP-open label extension: long-term benefits of inhaled iloprost addition to bosentan for treatment of pulmonary arterial hypertension. Poster presented at: annual meeting of the American Thoracic Society; San Francisco, CA: May (2007)
99. Hoeper M.M., Faulenbach C., Golpon H., Winkler J., Welte T., and Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Resp J 24 (2004) 1007-1010
100. Fleming T.R. Standard versus adaptive monitoring procedures: a commentary. Stat Med 25 (2006) 3305-3312